Table 2.
Deterministic Results over Lifetime Time Horizon
| Model-Generated Outcomes | |||||||
|---|---|---|---|---|---|---|---|
| Treatment | Cost: Health Sector Payer Perspective $ | Cost: Societal Perspective $ | Life-Years | QALYs | |||
| Sarilumab | 492,073 | 633,680 | 17.16 | 13.66 | |||
| Adalimumab | 535,667 | 688,819 | 17.05 | 13.35 | |||
| cDMARD (methotrexate) | 62,587 | 272,014 | 16.54 | 11.77 | |||
| Incremental Results (Incremental Cost per QALY Gained) | |||||||
| Perspective | Treatment | Comparator: cDMARD, $ | Comparator: Adalimumab | ||||
| Health sector payer | Sarilumab | 227,308 | Dominant | ||||
| Adalimumab | 298,877 | Reference | |||||
| Societal | Sarilumab | 191,414 | Dominant | ||||
| Adalimumab | 263,325 | Reference | |||||
cDMARD = conventional disease-modifying antirheumatic drug; QALY = quality-adjusted life-years.